Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atrial Fibrillation - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H1 2016', provides an overview of the Atrial Fibrillation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation - The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects - The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Atrial Fibrillation Overview 9 Therapeutics Development 10 Pipeline Products for Atrial Fibrillation - Overview 10 Pipeline Products for Atrial Fibrillation - Comparative Analysis 11 Atrial Fibrillation - Therapeutics under Development by Companies 12 Atrial Fibrillation - Therapeutics under Investigation by Universities/Institutes 13 Atrial Fibrillation - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Atrial Fibrillation - Products under Development by Companies 17 Atrial Fibrillation - Products under Investigation by Universities/Institutes 19 Atrial Fibrillation - Companies Involved in Therapeutics Development 20 ARCA biopharma, Inc. 20 AstraZeneca Plc 21 Bristol-Myers Squibb Company 22 Cardiome Pharma Corp. 23 Daiichi Sankyo Company, Limited 24 Gilead Sciences, Inc. 25 Ionis Pharmaceuticals, Inc. 26 Laboratoires Pierre Fabre SA 27 Nissan Chemical Industries, Ltd. 28 Nyken B.V. 29 Otsuka Holdings Co., Ltd. 30 Perrigo Company Plc 31 Xention Limited 32 Atrial Fibrillation - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 AFC-1 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BMS-394136 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 BMS-919373 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 bucindolol hydrochloride - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 edoxaban tosylate - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 F-373280 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 flecainide acetate - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 GS-967 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ISIS-CRPRx - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 landiolol - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 NIP-151 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 NYK-1112 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 OMT-28 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 OPC-108459 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ranolazine ER - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 vernakalant hydrochloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 XEN-R0702 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 XEND-0103 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 XENR-0703 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 XENR-0706 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Atrial Fibrillation - Recent Pipeline Updates 72 Atrial Fibrillation - Dormant Projects 87 Atrial Fibrillation - Discontinued Products 91 Atrial Fibrillation - Product Development Milestones 92 Featured News & Press Releases 92 Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA 92 Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia 92 Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant 92 Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015 93 Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation 94 Sep 23, 2015: UK's NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation 94 Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing 96 Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China 96 Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice" 96 Jun 25, 2015: Daiichi Sankyo's Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables Number of Products under Development for Atrial Fibrillation, H1 2016 10 Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Investigation by Universities/Institutes, H1 2016 19 Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H1 2016 20 Atrial Fibrillation - Pipeline by AstraZeneca Plc, H1 2016 21 Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2016 22 Atrial Fibrillation - Pipeline by Cardiome Pharma Corp., H1 2016 23 Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 24 Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H1 2016 25 Atrial Fibrillation - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 26 Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 27 Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H1 2016 28 Atrial Fibrillation - Pipeline by Nyken B.V., H1 2016 29 Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 30 Atrial Fibrillation - Pipeline by Perrigo Company Plc, H1 2016 31 Atrial Fibrillation - Pipeline by Xention Limited, H1 2016 32 Assessment by Monotherapy Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H1 2016 72 Atrial Fibrillation - Dormant Projects, H1 2016 87 Atrial Fibrillation - Dormant Projects (Contd..1), H1 2016 88 Atrial Fibrillation - Dormant Projects (Contd..2), H1 2016 89 Atrial Fibrillation - Dormant Projects (Contd..3), H1 2016 90 Atrial Fibrillation - Discontinued Products, H1 2016 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
